{
  "ticker": "EIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964324",
  "id": "02964324",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250701",
  "time": "0953",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9z3w9dg65y0.pdf",
  "summary": "- **FDA Submission Pathway**: Mayo Clinic Platform validation study for EchoSolv HF underway, final step before FDA submission in H2 CY25.  \n- **Key Milestone**: Study completion is last regulatory requirement prior to formal FDA 510(k) application.  \n- **Market Potential**: Heart failure represents a US$60bn annual market; EchoSolv HF targets leading cause of US rehospitalisations (17% of healthcare spend).  \n- **Partnership**: Mayo Clinic Platform collaboration includes potential adoption across 30 Mayo hospitals and co-branding rights.  \n- **Timing**: FDA clearance expected H2 CY25, aligning with prior guidance.  \n\n*No material capital markets or trading-specific information (e.g., raising, liquidity events) identified.*",
  "usage": {
    "prompt_tokens": 1373,
    "completion_tokens": 153,
    "total_tokens": 1526,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T23:59:16.058011"
}